Program
MK-7602
Its studies are mostly in Malaria, led by Merck.
Furthest: phase 1, since Feb 28, 20243 company-led studies, 1 open or runningNext primary completion: Apr 5, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 31 open or running | phase 1since Feb 28, 2024 | Feb 28, 2024 | Apr 5, 2027phase 1 · NCT07919028 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 28, 2024First study: phase 1 study in MalariaFirst studyNCT06294912 · 16 enrolled · Australia
- Jan 21, 2025Phase 1 study in HealthyNCT06797674 · 34 enrolled · United States
- Oct 30, 2026Phase 1 study in HealthyNCT07919028 · 24 planned
Ahead
- Apr 5, 2027Primary completion: phase 1 study in HealthyNCT07919028
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07919028Healthy | 1 | Not yet recruiting | Apr 5, 2027 | 24 |
| NCT06797674Healthy · United States | 1 | Completed | Aug 12, 2025 | 34 |
| NCT06294912Malaria · Australia | 1 | Completed | Jan 6, 2025 | 16 |
How it is read
Names in the registry
- “MK-7602”, 3 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.